Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer

被引:27
|
作者
Monge, A
Jagla, M
Lapouge, G
Sasorith, S
Cruchant, M
Wurtz, JM
Jacqmin, D
Bergerat, JP
Céraline, J
机构
[1] Univ Strasbourg 1, Lab Cancerol Expt & Radiobiol, EA 3430, IRCAD, F-67091 Strasbourg, France
[2] IGBMC, Dept Biol & Genom Struct, Illkirch Graffenstaden, France
[3] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France
[4] Hop Univ Strasbourg, Serv Chirurg Urol, Strasbourg, France
关键词
androgen receptor; hormone-refractory prostate cancer; mutation; DNA binding specificity; transcriptional activity;
D O I
10.1007/s00018-005-5471-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Missense mutations in the androgen receptor (AR) contribute to the failure of hormonal therapy for prostate cancer (PCa), but the underlying molecular bases remain uncharacterized. Here, we describe a new AR variant found in a hormone-refractory metastatic PCa, in which threonine 575 in the DNA binding domain, and threonine 877 in the ligand-binding domain, were both replaced by an alanine. Using gene reporter assays, we demonstrate that the T575A mutation weakened transcriptional activity from promoters containing AR-spe-cific responsive elements, while activity from promoters with AR-non-specific elements was enhanced. Data from gel shift experiments revealed a preferential binding of the T575A mutant to AR-non-specific motifs. We demonstrate that the two mutations T575A and T877A cooperate to confer new functional properties on the AR, and that the mutant AR functions simultaneously as a promiscuous AR due to the T877A mutation, and an unfaithful AR due to the T575A mutation.
引用
收藏
页码:487 / 497
页数:11
相关论文
共 50 条
  • [41] Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer
    Tanaka, Tomoaki
    Kawashima, Hidenori
    Matsumura, Kentaro
    Yamashita-Hosono, Tomoko
    Yoshimura, Rikio
    Kuratsukuri, Katsuyuki
    Harimoto, Koji
    Nakatani, Tatsuya
    ONCOLOGY REPORTS, 2009, 21 (01) : 33 - 37
  • [42] Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer
    Chiappino, Isabella
    Destefanis, Paolo
    Addeo, Alfredo
    Galetto, Alessandra
    Cucchiarale, Giuseppina
    Munoz, Fernando
    Zitella, Andrea
    Ferrando, Ugo
    Fontana, Dario
    Ricardi, Umberto
    Tizzani, Alessandro
    Bertetto, Oscar
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 234 - 238
  • [43] A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer
    Ferrero, JM
    Foa, C
    Thezenas, S
    Ronchin, P
    Peyrade, F
    Valenza, B
    Lesbats, G
    Garnier, G
    Boublil, JL
    Tchiknavorian, X
    Chevallier, D
    Amiel, J
    ONCOLOGY, 2004, 66 (04) : 281 - 287
  • [44] Taxanes in the chemotherapy of hormone-refractory prostate
    Johannsen, M
    Wilke, K
    Schnorr, D
    Loening, SA
    UROLOGE A, 2004, 43 (02): : 160 - 167
  • [45] Vinorelbine-based chemotherapy in hormone-refractory prostate cancer
    Zampino, M. G.
    Verri, E.
    Locatelli, M.
    Curigliano, G.
    Ascione, G.
    Sbanotto, A.
    Rocca, A.
    Verweij, F.
    Matei, V.
    Scardino, E.
    Decobelli, O.
    Goldhirsch, A.
    Nole, F.
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2375 - 2380
  • [46] ORAL ETOPOSIDE IN THE TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER
    HUSSAIN, MH
    PIENTA, KJ
    REDMAN, BG
    CUMMINGS, GD
    FLAHERTY, LE
    CANCER, 1994, 74 (01) : 100 - 103
  • [47] Effect of carboplatin on response and palliation in hormone-refractory prostate cancer
    Jungi, WF
    Bernhard, J
    Hurny, C
    Schmitz, SFH
    Hanselmann, S
    Gusset, H
    Pestalozzi, D
    Goldhirsch, A
    SUPPORTIVE CARE IN CANCER, 1998, 6 (05) : 462 - 468
  • [48] Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients
    Mencoboni, M
    Tredici, S
    Rebella, L
    Bergaglio, M
    Galbusera, V
    Manzara, A
    Claudiani, F
    Malcangi, B
    Varaldo, M
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2233 - 2235
  • [49] A role of somatostatin analogues in the treatment of patients with hormone-refractory prostate cancer
    Alekseev, B. Ya.
    Kaprin, A. D.
    Nyushko, K. M.
    ONKOUROLOGIYA, 2011, 7 (02): : 84 - 87
  • [50] Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer
    Nishiyama, T
    Terunuma, M
    UROLOGIA INTERNATIONALIS, 2000, 65 (01) : 28 - 31